Multiple sclerosis outcomes after cancer immunotherapy

Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder

(2018) L. Harinstein et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Neurologic complications of immune checkpoint inhibitors

(2018) Avi Fellner et al.   JOURNAL OF NEURO-ONCOLOGY

Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma

(2018) James C. Kuo et al.   MELANOMA RESEARCH

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

(2017) James L. Gulley et al.   JNCI-Journal of the National Cancer Institute

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Valery L Feigin et al.   LANCET NEUROLOGY

Neurological complications of new chemotherapy agents

(2017) Alicia M Zukas et al.   NEURO-ONCOLOGY

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

(2017) James Larkin et al.   ONCOLOGIST

Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

(2017) Justin C. Kao et al.   JAMA Neurology

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

(2017) James L. Gulley et al.   JNCI-Journal of the National Cancer Institute

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

(2016) Lisa Ann Gerdes et al.   ANNALS OF NEUROLOGY

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

(2016) Mayur Sarangdhar et al.   NATURE BIOTECHNOLOGY

P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab

(2016) L. Gómez Vicente et al.   NEURO-ONCOLOGY

CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment

(2016) Yonghao Cao et al.   NEUROLOGY

Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update

(2016) Kassandra Munger et al.   SEMINARS IN NEUROLOGY

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?

(2015) Gianmauro Numico et al.   PLoS One

Pathologic heterogeneity persists in early active multiple sclerosis lesions

(2014) Imke Metz et al.   ANNALS OF NEUROLOGY

Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

(2014) Edward J Gettings et al.   Multiple Sclerosis Journal

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

(2014) B. Liao et al.   NEURO-ONCOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients

(2012) S. S. Kwek et al.   JOURNAL OF IMMUNOLOGY

Epidemiology of Multiple Sclerosis

(2011) Sreeram V. Ramagopalan et al.   NEUROLOGIC CLINICS

‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants

(2010) Yehuda Shoenfeld et al.   JOURNAL OF AUTOIMMUNITY